Search PubMed⌕ Search

Biomedical subjects

D L Citrin

Publications and source records attributed to D L Citrin.

At least 55 records · Page 3Linked to original sources
PubMed1976

Radioactive technetium phosphate bone scanning in preoperative assessment and follow-up study of patients with primary cancer of the breast.

Seventy-five female patients with early primary cancer of the breast were studied by bone scanning with 99mTc labeled phosphate at the time of initial presentation and serially during follow-up examination. Eleven patients had an abnormal bone scan at the time of presentation. During follow-up periods, which have ranged from three to 34 months with a mean of 16 months, abnormal bone scans have developed in a further 13 patients. To date, nine of the 24 patients with an abnormal bone scan have died, while only one of the 51 with a persistently normal scan has died. It is concluded that an abnormal bone scan carries a significant risk of earlier death due to metastatic disease.

Adult↗
PubMed1975

The application of the 99Tcm phosphate bone scan to the study of breast cancer.

Comparison of the gamma camera bone scan and radiological survey in 190 patients with breast cancer has confirmed the superiority of the bone scan in the positive diagnosis of skeletal metastases. In 47 patients with known (X-ray positive) bony metastases the scan was positive in all but 2, and in 24 (50 per cent) the scan showed more lesions than the X-ray had indicated. In 60 patients with a clinical suspicion of bone metastases but negative X-rays, the scan was positive in 29 (48 per cent). Eighty-three patients with primary breast cancer were studied at the time of initial presentation. All had a normal radiographic skeletal survey but 24 (27 per cent) had scan evidence of occult metastases. It is concluded that a bone scan is indicated in all patients with breast cancer where skeletal metastases are suspected. Repeated bone scans may introduce new therapeutic possibilities, by providing an earlier objective index of progression of metastatic disease and also by providing a quantitative method of assessing the response to therapy.

Adult↗
PubMed1975

Dynamic studies with 99mTc-HEDP in normal subjects and in patients with bone tumors.

Blood clearance, urinary excretion, and spinal uptake of 99mTc-HEDP have been measured in ten normal control subjects. Blood clearance from 15 min is biexponential. Approximately 70% of the administered activity was excreted in the urine within 6 hr of injection. Spine-to-background ratios rise sequentially with time. Net normal bone uptake rises little after 2 hr and improved visualization of the normal skeleton therafter is due to reduction of blood background activity. In 13 patients with bone tumors, direct measurement of diphosphonate uptake by the tumor-involved and corresponding normal bone showed a continued rise in diphosphonate levels in the tumor-involved bone due to increased metabolic activity.

Adult↗